Across TCGA pan-cancer cohorts, RUFY2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RUFY2 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RUFY2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated RUFY2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC and LUAD are the cancer types where RUFY2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.662	.009	34	view →
LUAD	OS	Median	All	0.323	0.834	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RUFY2 tumor-vs-normal RNA expression · all RUFY2 data types